Wall Street brokerages expect Horizon Pharma PLC (NASDAQ:HZNP) to announce sales of $245.18 million for the current quarter, Zacks reports. Two analysts have issued estimates for Horizon Pharma’s earnings, with the lowest sales estimate coming in at $233.35 million and the highest estimate coming in at $257.00 million. Horizon Pharma posted sales of $220.86 million during the same quarter last year, which suggests a positive year over year growth rate of 11%. The business is expected to report its next earnings report on Monday, May 14th.
On average, analysts expect that Horizon Pharma will report full-year sales of $245.18 million for the current financial year, with estimates ranging from $1.15 billion to $1.17 billion. For the next year, analysts expect that the company will post sales of $1.25 billion per share, with estimates ranging from $1.19 billion to $1.30 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.07. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. The business had revenue of $274.22 million for the quarter, compared to analyst estimates of $264.48 million. During the same quarter in the prior year, the firm earned $0.64 EPS. The firm’s quarterly revenue was down 11.6% compared to the same quarter last year.
HZNP has been the topic of several analyst reports. Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and upped their target price for the stock from $12.00 to $18.00 in a report on Friday, January 12th. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Wednesday, February 28th. BidaskClub downgraded shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, February 21st. Cowen reiterated a “buy” rating and set a $24.00 price target on shares of Horizon Pharma in a research report on Thursday, March 1st. Finally, UBS set a $20.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $18.64.
A number of hedge funds and other institutional investors have recently modified their holdings of HZNP. Advantage Investment Management LLC lifted its position in Horizon Pharma by 164.8% during the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,900 shares in the last quarter. Brown Advisory Inc. acquired a new position in Horizon Pharma during the 3rd quarter valued at about $145,000. BlueCrest Capital Management Ltd acquired a new position in Horizon Pharma during the 4th quarter valued at about $160,000. K2 Principal Fund L.P. lifted its position in Horizon Pharma by 126.1% during the 4th quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 53,574 shares during the period. Finally, Zeke Capital Advisors LLC acquired a new position in Horizon Pharma during the 4th quarter valued at about $167,000. Institutional investors and hedge funds own 86.75% of the company’s stock.
HZNP stock traded down $0.08 on Thursday, hitting $14.57. 1,121,436 shares of the stock traded hands, compared to its average volume of 1,850,060. The company has a current ratio of 1.63, a quick ratio of 1.54 and a debt-to-equity ratio of 1.91. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $16.02. The company has a market cap of $2,458.68, a price-to-earnings ratio of -5.78, a price-to-earnings-growth ratio of 0.63 and a beta of 1.34.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.